ClinicalTrials.gg
CompletedNCT07259330Updated May 1, 2026

To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants

A Phase 1 interventional study of Nirogacestat and Nirogacestat and Cocktail of CYP Specific Probe Substrates in Healthy, sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This study will evaluate the effects of nirogacestat 100 mg twice daily (BID) on the pharmacokinetics (PK) of a cytochrome P450 (CYP) cocktail.

Read the detailed description

This is a single-center, single-sequence crossover study to assess the potential induction effects of nirogacestat on the PK of probe substrates for CYPs (CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4) in healthy adult men.

There will be a Screening Period of up to 33 days prior to Day -4. Eligible participants will be enrolled in the study and will complete a 3-day Lead-In Period, followed by an 18-day Treatment Period. A follow-up (FU) telephone call will be performed 26 to 28 days after the last dose of study treatment (Day 43 [+2]).

During Screening, participants will sign the informed consent form prior to any study procedures being performed. Participants must satisfy all the inclusion and exclusion criteria to be eligible for study participation. Participants will be admitted to the clinical research unit (CRU) on Day -4 for check-in procedures and eligibility confirmation.

Once eligibility is confirmed, participants will receive a CYP cocktail (CYP2B6 [bupropion], CYP2C8 [repaglinide], CYP2C9 [flurbiprofen], CYP2C19 [omeprazole], and CYP3A4 [midazolam]) on the morning of Day -3, following an overnight fast of at least 10 hours. The CYP cocktail will be administered orally.

Beginning on Day 1 through Day 17, participants will be administered 100 mg nirogacestat orally BID. On Day 15, following an overnight fast of at least 10 hours, participants will also receive a single oral dose of the CYP cocktail in the morning immediately following the oral dose of nirogacestat. On all other days, nirogacestat can be administered with or without food. Study treatment will be administered orally.

Assessments for safety along with serial samples of blood will be collected throughout the Lead-In and Treatment Period.

Participants will remain domiciled at the CRU until all safety evaluations are completed on Day 18.

Participants will complete a FU telephone visit on Day 43 (+2 days) for review of AEs/serious AEs and concomitant medications. Additional safety evaluations may be scheduled at the discretion of the investigator prior to the FU telephone visit.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant understands the study procedures, is willing to comply with all study requirements and restrictions and agrees to participate in the study by providing written prior to any study-related procedures being performed.
  2. Participant is a male between 18 and 55 years of age (inclusive) at the time of informed consent.
  3. Participant has a (BMI) ≥18 kg/m2 and ≤32 kg/m2 (inclusive) at Screening and Day -4, and a total body weight >50 kg.
  4. Participant is considered to be medically healthy, as determined by a responsible and experienced investigator, based on a clinical evaluation (including medical history, physical examination, clinical laboratory tests, vital sign measurements, and a 12-lead [ECG] and the results of clinical chemistry coagulation and urinalysis carried out at Screening and Day -4.
  5. Participant has , aspartate aminotransferase, and total levels less than 1.5×the at Screening and at Day -4.
  6. Participant has a renal function ( ≥90 mL/min), as evidenced by normal estimated measured by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at Screening and at Day -4.
  7. Participants that agree to the following during the Treatment Period, and for at least 7 days after the last dose of study treatment:

    1. Refrain from donating or preserving sperm; PLUS either
    2. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.

    OR c. Must agree to use a male condom when having sexual intercourse with women of (WOCBP). An additional form of must also be used by the female partner if she is of childbearing potential.

  8. Has sufficiently good venous access in at least 1 arm to confidently enable serial blood sampling.

Exclusion criteria

Exclusion Criteria:

  • 1. Participant has a history or presence of oncologic, cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, ocular, endocrine, immunologic, dermatologic, musculoskeletal, neurologic, psychiatric, or other disease or condition or the laboratory test abnormality that, in the investigator's judgment, poses a significant risk to the safety of the participant or the achievement of study objectives.

    2. Participant has a history or presence of any condition possibly affecting drug absorption (e.g., gastrectomy).

    3. Participant has a medical history or abnormal findings at Screening or Day -4 that the investigator judges may put at risk achieving the objectives of the study or protecting the safety of the participant.

    4. Participant has an acute illness with symptoms or treatment that has started or persisted within 14 days prior to study treatment administration, unless mild in severity, and enrollment is approved by both investigator and sponsor's medical monitor.

    5. Participant has tested positive for virus, virus, or , or has a infection.

    6. Participant has blood pressure (BP) that is ≥140 mmHg systolic or ≥90 mmHg diastolic following at least 5 minutes of supine rest at Screening or Day -4. Additionally, BP that is \<90 mmHg systolic or \<45 mmHg diastolic following at least 5 minutes of a supine rest at Screening or Day -4.

    7. Participant has heart rate (HR) that is \<40 bpm or >100 bpm after resting in a supine position for 5 minutes at Screening or Day -4.

    8. Participant has averaged corrected using Fridericia's formula results from valid triplicate ECGs >450 msec at Screening or Day -4.

    9. Participant has family history of long QT syndrome, or of unexplained sudden death or drowning in a first-degree relative under age 50.

    10. Participant has an waveform abnormality that interferes with QT/QTc interval measurement or interpretation. A participant with mild sinus arrhythmia or sparse isolated premature ventricular contractions is eligible at the investigator's discretion.

    11. Participant has a positive serum alcohol test or other drug screen test at Screening and/or Day -4.

    12. Participant has received any vaccine within 14 days prior to the first dose of study treatment administration on Day -3.

    13. Participant has received any inhibitors or inducers within 21 days or 5 half-lives (whichever is longer) prior to Day -3.

    14. Participant has had concurrent use of, or has used any long-acting gastric acid reducing agents, including histamine-2 receptor antagonists and proton pump inhibitors, including over-the-counter agents, in the last 21 days prior to Day -3.

    15. Participant has received any prescription or nonprescription drugs (including vitamins and dietary or herbal supplements) within 3 weeks or 5 half-lives, if known (whichever is longer), prior to study treatment administration on Day -3, unless in the opinion of the investigator and sponsor that the medication will not interfere with the study.

    16. Participant has received an product within 30 days or 5 times the half-lives, if known, of any drug used in the prior study (whichever is longer), or exposure to >4 new investigational agents within 12 months prior to study treatment administration on Day -3.

    17. Participant has a known or intolerance to any of the study treatments, or thereof, or a history of drug or other allergy that, in the opinion of the investigator or sponsor medical monitor, contraindicates their participation.

    18. Participant has a history of excessive intake of alcohol, defined as an average an average weekly intake of >21 units (1 unit is equivalent to 1 can or bottle [250 mL] of beer, or 1 measure [35 mL] of spirits, or 1 glass [100 mL] of wine) in the last 6 months prior to Screening.

    19. Participant has a history of illicit drug abuse within the past 2 years prior to Screening.

    20. Participant has consumed red wine or any fruit juices (including, but not limited to, grapefruit, grapefruit juice, pomelos, exotic citrus fruits, or grapefruit hybrids) within 72 hours of Day -4.

    21. Participant has used caffeine or other xanthine containing products (e.g., coffee, black tea, green tea, colas, cacao, guarana, guayusa, yerba mate) within 48 hours of Screening and Day -4.

    22. Participant regularly consumes excessive amounts (defined as >5 cups per day) of caffeine, xanthine-containing products, or energy drinks, as judged by the investigator.

    23. Participant has used tobacco- or nicotine-containing products within 2 months prior to Screening.

    24. Participant has donated blood or had a loss of >450 mL of blood within 60 days, or donation of plasma within 7 days prior to CRU admission on Day-4.

    25. Participant has received blood products within the 60 days prior to Screening.

    26. Participant is unwilling to avoid strenuous or unaccustomed activity, sunbathing, or contact sports within 96 hours prior to admission to the CRU and until discharge from the CRU.

    27. Participant is deemed unsuitable for this study in the opinion of the investigator for any additional reason, condition, or prior therapy.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Nirogacestat

    Nirogacestat 100 mg BID will be administered orally from Day 1 through Day 17

    Drug: Nirogacestat

  • Experimental
    Nirogacestat and CYP cocktail

    Nirogacestat 100 mg BID will be administered orally from Day 1 through Day 17 and an oral dose of CYP cocktail (CYP2B6 \[bupropion 20 mg\], CYP2C8 \[repaglinide 0.05 mg\], CYP2C9 \[flurbiprofen 10 mg\], CYP2C19 \[omeprazole 10 mg\], and CYP3A4 \[midazolam 1 mg\]) will be administered on Day -3, and again on Day 15.

    Drug: Nirogacestat and Cocktail of CYP Specific Probe Substrates

Interventions

  • 100 mg tablet Day 1 through Day 17

  • DrugNirogacestat and Cocktail of CYP Specific Probe Substrates

    Drug: Nirogacestat 100 mg tablet Day 1 through Day 17 and Drug: Cocktail of CYP Specific Probe Substrates administered Day 15.

06

What researchers measure

Primary outcomes

  1. Plasma area under the concentration-time curve from dosing extrapolated to infinity (AUCinf) and maximum observed plasma concentration (Cmax) for the CYP cocktail probes alone, and coadministered with nirogacestat.

    Area under the concentration-time curve from dosing extrapolated to infinity. AUCinf = (AUClast + Clast/Kel) where Clast is the plasma concentration at the last quantifiable timepoint estimated from the log-linear regression analysis and Kel is the terminal elimination phase rate constant estimated by linear regression based on observations justified to describe the terminal phase on the log-linear concentration-time profile.

    Time frame: CYP cocktail - Day -3 and Day 15 at predose (-60 minutes) and at 0.5, 1, 2, 3, 4, 6, 8, (10% nominal), 12, 24, 48, and 72 hours and nirogacestat Days 1 through 17 predose trough samples should be obtained within 1 hour of the nominal time from dosing.

  2. Maximum Observed Plasma Concentration (Cmax) of the CYP cocktail probes alone, and coadministered with nirogacestat.

    Maximum observed plasma concentration. Observed directly from the data.

    Time frame: CYP cocktail - Day -3 and Day 15 at predose (-60 minutes) and at 0.5, 1, 2, 3, 4, 6, 8, (10% nominal), 12, 24, 48, and 72 hours and nirogacestat Days 1 through 17 predose trough samples should be obtained within 1 hour of the nominal time from dosing.

Secondary outcomes

  1. Plasma AUClast for the CYP cocktail probes alone and coadministered with nirogacestat.

    Area under the concentration-time curve from dosing to time of the last quantifiable concentration. Linear-log trapezoidal method.

    Time frame: CYP cocktail - Day -3 and Day 15 at predose (-60 minutes) and at 0.5, 1, 2, 3, 4, 6, 8, (10% nominal), 12, 24, 48, and 72 hours and nirogacestat Days 1 through 17 predose trough samples should be obtained within 1 hour of the nominal time from dosing.

  2. Plasma time of maximum observed concentration (Tmax) for the CYP cocktail probes alone and coadministered with nirogacestat.

    Time of maximum observed concentration. Observed directly from the data as the time of first occurrence of Cmax

    Time frame: CYP cocktail - Day -3 and Day 15 at predose (-60 minutes) and at 0.5, 1, 2, 3, 4, 6, 8, (10% nominal), 12, 24, 48, and 72 hours and nirogacestat Days 1 through 17 predose trough samples should be obtained within 1 hour of the nominal time from dosing.

  3. Plasma apparent terminal elimination half-life (t1/2) for the CYP cocktail probes alone and coadministered with nirogacestat.

    Apparent terminal elimination half-life calculated as ln(2)/Kel.

    Time frame: CYP cocktail - Day -3 and Day 15 at predose (-60 minutes) and at 0.5, 1, 2, 3, 4, 6, 8, (10% nominal), 12, 24, 48, and 72 hours and nirogacestat Days 1 through 17 predose trough samples should be obtained within 1 hour of the nominal time from dosing.

  4. Plasma apparent oral clearance (CL/F) for the CYP cocktail probes alone and coadministered with nirogacestat.

    Apparent oral clearance. Calculated as Dose/AUCinf

    Time frame: CYP cocktail - Day -3 and Day 15 at predose (-60 minutes) and at 0.5, 1, 2, 3, 4, 6, 8, (10% nominal), 12, 24, 48, and 72 hours and nirogacestat Days 1 through 17 predose trough samples should be obtained within 1 hour of the nominal time from dosing.

  5. Plasma apparent oral volume of distribution (Vd/F) for the CYP cocktail probes alone and coadministered with nirogacestat.

    Apparent oral volume of distribution. Calculated as Dose/(AUCinf × Kel).

    Time frame: CYP cocktail - Day -3 and Day 15 at predose (-60 minutes) and at 0.5, 1, 2, 3, 4, 6, 8, (10% nominal), 12, 24, 48, and 72 hours and nirogacestat Days 1 through 17 predose trough samples should be obtained within 1 hour of the nominal time from dosing.

  6. Plasma AUClast of respective probe substrate metabolites alone and coadministered with nirogacestat and the metabolite(s) to parent molar ratio for AUClast (MRAUClast), AUCinf (MRAUCinf), and Cmax (MRCmax) (as data permit).

    Area under the concentration-time curve from dosing to time of the last quantifiable concentration. Linear-log trapezoidal method.

    Time frame: CYP cocktail - Day -3 and Day 15 at predose (-60 minutes) and at 0.5, 1, 2, 3, 4, 6, 8, (10% nominal), 12, 24, 48, and 72 hours and nirogacestat Days 1 through 17 predose trough samples should be obtained within 1 hour of the nominal time from dosing.

  7. Plasma Cmax of respective probe substrate metabolites alone and coadministered with nirogacestat and the metabolite(s) to parent molar ratio for AUClast (MRAUClast), AUCinf (MRAUCinf), and Cmax (MRCmax) (as data permit).

    Maximum observed plasma concentration. Observed directly from the data.

    Time frame: CYP cocktail - Day -3 and Day 15 at predose (-60 minutes) and at 0.5, 1, 2, 3, 4, 6, 8, (10% nominal), 12, 24, 48, and 72 hours and nirogacestat Days 1 through 17 predose trough samples should be obtained within 1 hour of the nominal time from dosing.

  8. Plasma Tmax of respective probe substrate metabolites alone and coadministered with nirogacestat and the metabolite(s) to parent molar ratio for AUClast (MRAUClast), AUCinf (MRAUCinf), and Cmax (MRCmax) (as data permit).

    Time of maximum observed concentration. Observed directly from the data as the time of first occurrence of Cmax.

    Time frame: CYP cocktail - Day -3 and Day 15 at predose (-60 minutes) and at 0.5, 1, 2, 3, 4, 6, 8, (10% nominal), 12, 24, 48, and 72 hours and nirogacestat Days 1 through 17 predose trough samples should be obtained within 1 hour of the nominal time from dosing.

  9. Serum nirogacestat, trough concentration (Ctrough).

    Pre-dose concentration. Observed directly from the data.

    Time frame: Days 1 through 17 predose trough samples should be obtained within 1 hour of the nominal time from dosing.

  10. Number of participants with Adverse Events

    An adverse event (AE) was defined as any untoward medical occurrence in a participant. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a study intervention. A serious adverse event (SAE) was any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important.

    Time frame: Baseline (Day -4) through the Follow-up Phone Call (Day 43)

  11. Number of Participants With Clinically Meaningful Change From Baseline in Laboratory Values

    Number of participants with clinically significant change from baseline in laboratory parameters were reported. Clinical Significance was decided by the investigator. Laboratory investigation included hematology, biochemistry, urinalysis, and coagulation.

    Time frame: Baseline (Day -4) through Day 18

  12. Number of Participants With Clinically Meaningful Change From Baseline in Vital Signs

    Number of participants with clinically significant change from baseline in vital signs. Clinical Significance was decided by the investigator. Vital signs included oral body temperature, systolic blood pressure, diastolic blood pressure, and pulse rate.

    Time frame: Baseline (Day -4) through Day 18

  13. Number of Participants With Clinically Meaningful Change From Baseline in Electrocardiogram (ECG)

    Number of participants with clinically significant change from baseline in ECG parameters were reported. Clinical Significance was decided by the investigator. The 12-lead ECGs were recorded after the participants have rested for at least 5 minutes in supine position. The parameters included heart rate (HR), Respiratory Rate, Pulse Rate, QRS, QT, QTcB and QTcF

    Time frame: Baseline (Day -4) through Day 18

  14. Number of Participants With Clinically Meaningful Change From Baseline in Physical Exams

    A comprehensive physical examination will include, at a minimum, assessments of the cardiovascular, respiratory, gastrointestinal, and neurologic systems. Height and weight will also be measured and recorded. A symptom-directed physical examination will include, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen).

    Time frame: Baseline (Day -4) through Day 18

07

Study locations

1 site
  • ICON Martini Groningen CRU
    Groningen, 9728 NZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Mar 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 2, 2025
StartActual
Oct 27, 2025
Primary completionActual
Mar 27, 2026
CompletionActual
Mar 27, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07259330
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Oct 27, 2025
Primary completion
Mar 27, 2026
Completion
Mar 27, 2026
Last update
May 1, 2026

Study contacts

Jeroen van de Wetering, MD
principal investigator · ICON plc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion